NCT07755956
Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
At risk: Enrollment reduced 33%.
See at-risk trials from Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study sites: 1 to 2
- Interventions modified
- Notable Enrollment reduced: 30 → 20 participants
- Start date pushed from Aug 31, 2026 to Oct 31, 2026
- Eligibility criteria expanded, about 14 words
- Notable Recruitment opened
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Concentrations of leuprorelin acetate
Timeframe: Baseline through 70 days post-dose
Concentrations of estradiol
Timeframe: Baseline through 70 days post-dose
Secondary (2)
Number of participants with Adverse events
Changes from baseline in overall pain score
Arms and interventions
HHK001Experimental
EnantoneActive comparator
Drugs: HHK001, Enantone
Sites
2 sites in 1 country